+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 26 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.

Age: 18Years +All GendersPhase 3
317 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of standard chemotherapy with or without the drug INCB161734 in people with metastatic pancreatic ductal adenocarcinoma PDAC that has a specific KRAS G12D mutation. This is a Phase 3 randomized, double-blind trial aiming to compare these treatments in patients who have not received prior systemic treatment for their metastatic cancer. Participants will receive either oral INCB161734 tablets or placebo tablets alongside chemotherapy chosen by the investigator, either mFOLFIRINOX or GemNabP, as per the study protocol. The study compares these two groups to assess outcomes such as survival and response to treatment. Treatment and observation will continue for up to approximately two to three years depending on the outcome being measured. During the trial, participants will undergo regular assessments including survival monitoring, tumor response evaluations by blinded independent central review and investigator assessments, and quality of life questionnaires. Researchers will also monitor adverse events and organ function. The study involves scheduled visits and tests over the course of treatment and follow-up lasting up to several years to understand long-term effects and treatment impact.

Age: 18Years +All GendersPhase 3
230 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of standard chemotherapy combined with bevacizumab, with or without the addition of INCA33890, for the first-line treatment of adults with metastatic microsatellite stable colorectal cancer who have not received prior systemic treatment for metastatic disease. This phase 3 randomized, double-blind study aims to compare these treatment approaches to better understand their impact on disease progression. Participants will receive either INCA33890 or a placebo in combination with bevacizumab and FOLFOX chemotherapy at doses defined by the study protocol. The treatments are given as part of a randomized, parallel group design where neither the participants nor the investigators know which treatment is assigned. This study will assess outcomes over several years, with primary evaluation focused on progression-free survival for up to 3 years. Throughout the study, participants will be monitored regularly for treatment response, survival, and safety through various assessments including laboratory tests and quality of life questionnaires. Researchers will measure overall survival, objective response rate, duration of response, and treatment-related adverse events for up to 4 years. Quality of life changes will also be tracked using validated questionnaires. The total duration of participation may extend up to around 4 years, with ongoing safety and efficacy evaluations.

Age: 18Years +All GendersPhase 3
297 locations
P

Actively Recruiting

Researchers are studying an experimental drug called linvoseltamab in adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplantation. The study aims to compare the effects and safety of linvoseltamab combined with standard treatment against the standard treatment alone. This is a Phase 3 randomized, open-label trial sponsored by the European Myeloma Network B.V. Participants will receive either the combination of daratumumab, lenalidomide, dexamethasone, and linvoseltamab or continued treatment with daratumumab, lenalidomide, and dexamethasone alone. Treatments will be given according to the study protocol, and participants will be randomly assigned to one of these two groups. The study will continue for up to 11 years to assess long-term effects. During the study, participants will undergo various assessments including measurements of minimal residual disease MRD, progression-free survival, overall survival, and response rates. Quality of life will also be evaluated using standardized questionnaires. Safety will be closely monitored by tracking adverse events and laboratory tests. Participants will be followed up for up to 11 years, with regular visits to assess disease status and treatment impact.

Age: 18Years +All GendersPhase 3
59 locations
A

Actively Recruiting

This trial investigates polyomavirus infections BKPyV in people who have received kidney or simultaneous pancreas-kidney transplants. The study aims to evaluate how reducing or modifying immunosuppression, with or without intravenous immunoglobulin IVIG, affects BKPyV infection, transplant function, graft loss, acute rejection, immunosuppression levels, and survival. BKPyV infection is a serious complication due to the immune system suppression needed after transplantation, which can increase infection risks and damage the transplant. Participants will be randomly assigned to one of two groups one receiving immunosuppression reduction or modification plus IVIG, and the other receiving immunosuppression reduction or modification alone as part of standard care. The immunosuppression adjustments may include dose reductions or switches to less potent medications. IVIG is an antibody treatment with potential antiviral and immune-modulating effects, used here as an additional therapy for BKPyV infection. During the study, participants will be monitored for up to 48 weeks with assessments including viral load, kidney function eGFR, transplant rejection, antibody presence, infection events, hospitalizations, quality of life, cancer diagnosis, and adverse events. The main outcome measured at 11 to 13 weeks combines death, graft loss, kidney function decline, rejection, viral load, and immunosuppression load. Safety and treatment effects will be closely followed throughout the study period.

Age: 2Years +All GendersPhase 3
13 locations
S

Actively Recruiting

This research focuses on people aged 55 and older who have or may have clonal haematopoiesis CH, a condition where a group of blood-forming stem cells with specific mutations grows abnormally. CH is common in older adults and can increase the risk of serious health issues like blood cancers, heart disease, and strokes. The study aims to better understand CH detection, outcomes, and patient experiences, helping to guide future care and research in Australia. Participants confirmed or suspected to have CH will be invited to a specialized clinic for molecular testing and monitoring. The study will establish a registry to track their health over time, with regular visits scheduled for assessments. These visits will include blood tests and evaluations to monitor for complications, quality of life, psychological well-being, and disease progression. The study also offers personalized support to participants based on their condition. During the study, participants will provide blood samples and health information at multiple visits over five years, starting with screening and continuing with follow-ups at weeks 6, 52, 104, 156, 208, and 260. Researchers will assess changes in blood cell markers, psychological distress, and participants understanding of CH. The study will create a detailed database to help doctors improve CH care and support future research efforts.

Age: 55Years +All Genders
1 location
E

Actively Recruiting

Researchers are evaluating the effect and safety of orforglipron taken once daily in adults with Fontaine Stage II peripheral arterial disease PAD, a condition that causes symptoms like leg pain due to poor blood flow. The study is a phase 3 randomized, double-blind, placebo-controlled trial aiming to better understand how this treatment impacts walking ability and quality of life in this population. Participation is expected to last about 58 weeks. Participants are randomly assigned to receive either orforglipron or a placebo, both taken orally once daily. The study compares these two groups to assess changes in walking distances and other health measures over the course of the trial. This design helps evaluate the medications effect compared to no active treatment. During the study, participants undergo assessments including measuring maximum and pain-free walking distances, vascular quality of life via questionnaire, the six-minute walk test, blood markers like high-sensitivity C-reactive protein, and systolic blood pressure. These measurements occur at the start and after 52 weeks of treatment. Safety and effectiveness are monitored throughout, with overall participation lasting nearly a year.

Age: 18Years +All GendersPhase 3
169 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating ways to improve hepatitis C virus HCV care in drug treatment clinics and needle and syringe programs in New South Wales and across Australia. The ETHOS II Project aims to develop a framework to establish HCV screening and treatment programs in these settings nationally. This collaborative research involves several health organizations and focuses on people with a history of injecting drug use or those receiving opioid substitution therapy. The study includes an intervention called campaign days where participants receive hepatitis C screening, liver fibrosis assessments using fibroscans, and clinical assessments. Participants also complete surveys and may consent to link their data with population databases. A sub-study involves collecting blood samples from some participants to evaluate new diagnostic tests for chronic HCV infection. Additionally, interviews with policymakers, clinicians, and patients will explore barriers to HCV care, and an education program will be developed to improve workforce knowledge and care quality. Participants will be recruited from drug treatment clinics, general practitioners with high case loads, and needle and syringe programs. They will undergo hepatitis C testing, fibroscans, clinical assessments, and complete questionnaires during the campaign days. Researchers will track how many participants start anti-HCV treatment each year for up to three years. The study also includes follow-up through medical record reviews to monitor outcomes and improve treatment access and delivery.

Age: 18Years +All GendersPhase Not Applicable
32 locations
S

Actively Recruiting

Researchers are investigating new ways to test drug combinations aimed at killing tumor cells in patients with acute myeloid leukemia AML. This observational study focuses on whether using AML cells from individual patients in special mice that can accept human tissue can speed up the discovery of better treatments. It also evaluates if these mice show treatment responses similar to the actual AML patients from whom the cells were taken. Participants in this study are individuals with AML who are receiving the standard treatment of venetoclax and azacitidine. Blood and bone marrow samples will be collected from these patients to create patient-derived xenografts PDX in mice. These mice models mimic the patients disease and treatment response, allowing researchers to test standard and multiple experimental therapies simultaneously over a period of up to two years. The study aims to generate at least 20 adult AML PDX models linked with detailed clinical data. During the study, participants will provide samples before and after starting venetoclax plus azacitidine therapy. Researchers will measure leukemic cell frequency and characteristics using flow cytometry in both the mouse models and patient samples. The main outcomes include the successful creation of AML PDX models and the evaluation of their treatment responses over up to 52 weeks. This approach supports precision therapies tailored to specific tumor profiles and may accelerate future clinical trials of promising drug combinations.

Age: 18Years +All Genders
4 locations

1-10 of 26

1